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Abstract
Background: Telomerase expression is detectable in 81–95% of breast carcinomas and may serve
as a therapeutic target. The objective of this study was to investigate repression of telomerase
activity in primary ductal breast cancer cells through transcriptional regulation of the catalytic
subunit hTERT. We hypothesized that inhibition of telomerase expression could be achieved via
Tat mediated protein transduction of the repressor protein E2F-1.
Methods: Protein purification techniques were refined to yield biologically active Tat fusion
proteins (TFPs) capable of transducing the breast cancer cell lines HCC1937 and HCC1599. Cell
lines were treated with wildtype E2F-1 (E2F-1/TatHA), mutant E2F-1 (E132/TatHA) and a control
Tat peptide (TatHA) for 24 hours. Total RNA was isolated from treated cells, reverse transcribed
and fold changes in gene expression for hTERT determined via real-time RT-qPCR.
Results: Significant repression of the catalytic subunit of telomerase (hTERT) was present in both
HCC1937 and HCC1599 cells following treatment with E2F-1/TatHA. In HCC1937 cells, hTERT
was repressed 3.5-fold by E2F-1/TatHA in comparison to E132/TatHA (p < 0.0012) and the TatHA
peptide controls (p < 0.0024). In HCC1599 cells, hTERT was also repressed with E2F-1/TatHA
treatment by 4.0-fold when compared to the E132/TatHA control (p < 0.0001). A slightly lower
hTERT repression of 3.3-fold was observed with E2F-1/TatHA in the HCC1599 cells when
compared to the TatHA control (p < 0.0001).
Conclusion: These results suggest that transduction of E2F-1/TatHA fusion proteins in vitro is an
effective repressor of hTERT expression in the primary ductal breast cancer cell lines HCC1937
and HCC1599.
Background
Telomerase activity is detectable in 80–90% of malignan-
cies and is absent in most normal somatic cells [1]. Breast
cancer has been identified as an important target for
developing telomerase inhibitors. Importantly, fine-nee-
dle aspirations of malignant breast tumors revealed that
81% were positive for telomerase [2], and Hiyama et al.
(2000) also reported that 95% of advanced stage breast
cancers express telomerase [3]. Due to the majority of
tumor cells expressing telomerase, this protein is being
evaluated as a tumor marker for breast cancer and other
solid malignancies [4].
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Telomerase, a ribonucleoprotein, synthesizes tandem
repeats of the DNA sequence TTAGGG at the terminal
ends of chromosomes permitting continuous genomic
replication and cell division. Telomerase includes an RNA
component (hTR) that serves as the template for telomeric
DNA and a protein catalytic subunit (hTERT) with reverse
transcriptase activity [5]. The activity of telomerase is reg-
ulated by the transcription of hTERT, and the cloning and
characterization of the hTERT-promoter has permitted
examination of elements controlling transcriptional acti-
vation and repression of hTERT [6].
To impact expression of hTERT in breast cancer cells, our
research will utilize the E2F-1 transcription factor. The E2F
family of transcription factors mediates cell cycle progres-
sion, and they are released upon phosphorylation of
Retinoblastoma (Rb) family proteins [7-9]. While most of
these factors are associated with inducing gene expression,
E2F-1 has been identified as a transcriptional repressor of
the hTERT gene, specifically binding to two separate sites
(-174 bp and -98 bp) of the proximal hTERT promoter [7].
In addition, a study that examined the apoptotic function
of E2F-1 found that cell death generated by ectopic expres-
sion of E2F-1 was independent of the p53 regulatory path-
way [8]. Therefore, even in cells with intact p53
suppressor gene function, overexpression of E2F-1 should
inhibit transcription of the hTERT gene and potentially
induce apoptosis. Previous studies utilizing adenoviral-
mediated transfection of E2F-1 genes induced apoptosis
of melanoma cells [10], and an additional study revealed
that E2F-1 suppressed cell growth while decreasing telom-
erase activity in the Tu-167 SCCHN cell line [11]. Adeno-
viral-mediated overexpression of E2F-1 also induced
apoptosis in human breast and ovarian carcinoma cell
lines independently of p53 [12]. We anticipate that telom-
erase repression via E2F-1 protein therapy could induce
apoptotic activity and/or cell senescence in cancer cells
more effectively than the viral-based studies described
above.
Tat-mediated protein transduction was utilized in our
research to effectively target cancer cells. Transduction
occurs in a receptor- and transporter-independent fash-
ion, targets the lipid bilayer, and also crosses the blood-
brain barrier [13]. Tat has been reported to transduce
100% of mammalian cells, and studies also suggest the
transcriptional effects of Tat-mediated protein transduc-
tion are reversible and have no detrimental effects because
clearance of transduced proteins is dependent on the half-
life of the protein [13-15]. Becker-Hapak et al. [14] also
reported that Tat-mediated transduction is concentration
dependent, reaches maximum intracellular concentration
in less than 5 minutes, and nearly equal intracellular con-
centrations of the fusion proteins have been detected
between all transduced cells.
Our research investigated primary infiltrating ductal carci-
noma cells, both with and without a BRCA1 gene muta-
tion. In 2001, published results by Ho et al. [16]
determined that E2F-1 and E2F-4 were decreased in pri-
mary breast carcinomas, and 70% of the tumors revealed
decreased expression of E2F-1. Additionally, the meta-
static nodal tissue examined indicated that 100% of the
tissue samples had significantly low levels of E2F-1 as
compared to normal breast tissue. Ho et al. also suggested
that E2Fs act as tumor suppressors in breast cancer and
their down-regulation may be important in the develop-
ment of metastases [16]. It is important to determine the
repressive effects of E2F-1 on hTERT transcription in
tumor cells with and without the normal BRCA1 protein
to determine any variance between BRCA1 status and
inhibition of telomerase. Recently, Wang et al. [17] deter-
mined that the BRCA1 promoter was transactivated in a
dose-dependent manner by E2F-1 and served as a target
for E2F-dependent transcriptional regulation. Other stud-
ies have also demonstrated that BRCA1 is a potent inducer
of apoptosis by binding directly to p53 and stimulating
transcriptional activation of pro-apoptotic genes such as
Bax [18,19]. Therefore, telomerase inhibition in the pri-
mary infiltrating ductal carcinoma cell line with a BRCA1
gene mutation, HCC1937, will be compared to a breast
cancer cell line without detectible BRCA1 gene mutations,
HCC1599. Aside from variance in BRCA1 status, both
HCC1937 and HCC1599 cell lines carry similar muta-
tions in p53, Her2/neu and ER/PR receptors [20].
Here we report the first results of the repressive effects of
E2F-1 on telomerase activity using Tat-mediated transduc-
tion. These studies validated our proposed hypothesis that
telomerase activity can be repressed in infiltrating ductal
carcinoma cells via transcriptional regulation of hTERT
utilizing protein transduction techniques with E2F-1 Tat
fusion proteins.
Results
We were able to successfully produce E2F-1/Tat fusion
peptides utilizing both wildtype and mutant E2F-1 expres-
sion vectors to investigate their transcriptional effects on
hTERT. Techniques were modified to produce both E2F-1/
TatHA and E132/TatHA recombinant proteins (see Figure
1) and recombinant protein production was verified via
western blotting. Protein transduction was determined in
each cell line via immunocytochemistry, and the results
supported effective transduction of E2F-1/TatHA, E132/
TatHA and TatHA into all cell types. The TFPs were
detected throughout the cell cytoplasm with perinuclear
localization and detectable nuclear accumulation (Figure
2). The series of immunocytochemistry experiments rang-
ing from 1 hour to 24 hours incubation with TFPs all
revealed successful transduction of recombinant proteins
into greater than 95% of carcinoma cells.Molecular Cancer 2008, 7:28 http://www.molecular-cancer.com/content/7/1/28
Page 3 of 10
(page number not for citation purposes)
Our experiments were only performed with freshly dia-
lyzed proteins to avoid protein precipitation and to
ensure biological activity of proteins. The proteins were
added to cells for 24 hours to assess differences in hTERT
expression between the wildtype E2F1/TatHA protein,
mutant E2F-1 (E132/TatHA) and the TatHA control pro-
tein. Following RNA isolation and real-time RT-qPCR,
results revealed significant repression of hTERT in both
HCC1937 and HCC1599 breast cancer cells. In HCC1937
cells, E2F-1/TatHA greatly repressed hTERT by 3.5-fold (p
< 0.0024) (Figure 3) in comparison to the TatHA control
proteins. Furthermore, the cells treated with E132/TatHA
did not reveal effective repression of hTERT in compari-
son to TatHA (p < 0.6484).
In HCC1599 cells, a significant 3.3-fold repression of
hTERT gene expression was observed with E2F-1/TatHA
protein treatment versus the TatHA control protein (p <
0.0001) following 24 hours of treatment (Figure 3). Also,
a slightly increased expression of hTERT (1.15-fold
increase) was observed in TatHA treated HCC1599 cells
versus the E132/TatHA protein, but this difference was
only marginally statistically significant (p < 0.0102) (Fig-
ure 3). Further testing will be performed to assess differ-
ences between E132/TatHA and TatHA control proteins in
larger in vitro test groups.
Minimal differences in hTERT expression were detected in
HCC1937 and HCC1599 cells based on the BRCA1 status.
As previously mentioned, the HCC1937 cell line has a
homozygous BRCA1 mutation (5382C) in addition to
mutations in p53, Her2/neu and ER/PR receptors. In con-
trast, the HCC1599 cell line expresses the wildtype BRCA1
tumor suppressor gene but also contains mutations in
p53, Her2/neu and ER/PR receptors. A slightly higher
repression of hTERT was observed in HCC1599 cells (4.0-
fold) versus HCC1937 (3.5-fold) when E2F-1/TatHA was
compared to the E132/TatHA control, but this slight dif-
ference in hTERT repression is most likely not attributed
to the difference in BRCA1 status.
Discussion
The results from this study suggest that E2F-1/TatHA is a
moderately effective repressor of hTERT. In comparison to
E132/TatHA and TatHA controls, hTERT was repressed by
3.3 to 4.0-fold in HCC1937 and HCC1599 breast carci-
noma cells. The efficient transduction of the E2F-1/TatHA
peptides into breast cancer cells combined with their tran-
scriptional effects on hTERT expression suggests an alter-
nate route to inhibit telomerase expression in breast
cancer cells. The extent of hTERT repression in our study
is comparable to the results observed by Crowe et al.'s
study (2001) which suggests that our alternative route of
introducing the E2F-1 transcription factor into cancer cells
does not result in greater repression of hTERT than lipo-
some-mediated transfection of E2F-1 [7]. However, the
introduction of biologically active E2F-1/TatHA proteins
has potential benefits. Treatment with our wildtype and
mutant TFPs results in reversible repression of hTERT
which could serve as a modality to augment the effects of
other chemotherapeutic or apoptotic agents. This particu-
lar study did not examine the direct effects on apoptosis,
but continued treatment with E2F-1/TatHA proteins
could serve to effectively repress hTERT leading to long-
term telomerase repression.
SDS-PAGE gels of recombinant E2F-1/TatHA and E132/ TatHA proteins Figure 1
SDS-PAGE gels of recombinant E2F-1/TatHA and 
E132/TatHA proteins. SDS-PAGE gels of recombinant 
E2F-1/TatHA and E132/TatHA proteins. (A) SDS-PAGE gel 
of E2F-1/TatHA purified protein. Lane 1, Protein molecular 
weight marker. Lane 2, E2F-1/TatHA expressing culture. Lane 
3, FPLC purified E2F-1/TatHA protein (60 kDa). (B) SDS-
PAGE gel of E132/TatHA purified protein. Lane 4, Protein 
molecular weight marker. Lane 5, E132/TatHA expressing 
culture. Lane 6, FPLC purified E132/TatHA protein (60 kDa).
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Immunocytochemistry images of HCC1937 cells Figure 2
Immunocytochemistry images of HCC1937 cells. Immunocytochemistry images of HCC1937 cells transduced with Tat 
fusion proteins for 24 hours. (A) Cells treated with 2 μM E2F-1/TatHA. (B) Cells treated with 2 μM E132/TatHA. (C) Cells 
treated with 2 μM TatHA control peptide. Images were captured using the 40× objective on the Bio-Rad MRC 1024 Laser 
Scanning Confocal Microscope.
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To interpret the results of our hTERT repression studies, it
is important to review the expected effects of E2F-1/TatHA
treatment of cells versus E132/TatHA and control peptide
TatHA. Crowe et al. determined the normal E2F-1 expres-
sion vector binds to two sites of the hTERT promoter and
represses its transcription by approximately 4-fold in their
study [7]. The negative control, mutant E2F-1, referred to
as E132/TatHA in our research, has a point mutation in
the DNA-binding domain and cannot bind to the E2F-1
binding sites on the hTERT promoter and exhibited no
repressive effects on hTERT [7]. We expected to observe
similar results in our study, and since Tat-mediated pro-
tein transduction is an effective method of delivering bio-
logically active proteins into cells, we hoped to achieve
greater than 4.0-fold repression of hTERT in our study.
However, as demonstrated by our data following 24 hours
of treatment with E2F-1/TatHA, only a maximum of 4-
fold hTERT repression was observed in HCC1599 cells.
The characterization of E2F-1 as a transcriptional repres-
sor is a controversial role for this factor because it has tra-
ditionally been denoted as a transactivator of various
genes. Hsieh et al. [21] reported that transcriptional
repression rather than the transactivation function of E2F-
1 is involved in the induction of apoptosis. Zhang et al.
[19] provided the first direct evidence that telomerase is
required for maintaining the vitality of both human
tumor and immortal cells. Zhang et al. also reported that
cell death in immortal cells was telomere-length depend-
ent, and upon inhibiting telomerase in cells with short tel-
omeres, the resulting damage to the chromosomes
triggered apoptotic cell death [19]. Interestingly, Yama-
saki et al., [22] determined that E2F-1 null mutant mice
developed a variety of malignant tumors, and Field et al.
[23] indicated that E2F-1 functions in mice to promote
apoptosis and suppress cell proliferation. Tumor forma-
tion in the absence of E2F-1 was also suggested by Crowe
et al. [7]. Their study utilized E2F-1 expression vectors and
liposomal transfection into SCC25 cells resulting in tran-
scriptional repression of hTERT via consensus binding in
the hTERT- promoter at putative E2F-1 sites [7]. Impor-
tantly, Crowe et al. reported that transfection of the E2F-1
constructs reduced endogenous hTERT mRNA levels by 4-
fold, and the reduced hTERT mRNA levels were accompa-
nied by decreasing telomerase activity [7]. The study by
Crowe et al. was one of the first to correlate the novel tran-
scriptional repressive effects of E2F-1 on the hTERT gene
promoter while monitoring subsequent telomerase activ-
ity [7]. However, the repressive effects of E2F-1 on hTERT
must be further examined in future studies. The liposome-
mediated transfection of E2F-1 via the Lipofectamine™ kit
(Invitrogen Life Technologies, Carlsbad, CA) as described
in Crowe et al. does not guarantee transfection of 100% of
the cancer cells [7], nor do any of the adenoviral-mediated
studies previously mentioned [10-12]. Therefore, to deter-
mine if E2F-1 can completely repress hTERT transcription,
the E2F-1 protein must be effectively transduced into
100% of the cancer cells. Our research suggested greater
than 95% transduction rates with E2F-1 TFPs, but maxi-
mum hTERT repression was only 4-fold with our alterna-
tive mode of transduction, which is comparable to results
published by Crowe et al [7]. Complete repression of
hTERT was not observed in our study using TFPs suggest-
ing that a combination of transcriptional repressors may
be required when using Tat-mediated transduction to
completely inhibit expression of hTERT. It must be noted,
that to date, complete gene repression has only been dem-
onstrated utilizing gene knockout protocols and models.
There are, however, significant advantages of using our
method of transducing E2F-1 TFPs over transfection pro-
tocols. One is the simplicity of being able to use a TAT-
peptide to transport any denatured protein inside the cell.
Another is that it alleviates the deleterious effects associ-
ated with viral based DNA transfection procedures and
Fold repression of hTERT gene expression in breast cancer  cell lines- TatHA control Figure 3
Fold repression of hTERT gene expression in breast 
cancer cell lines- TatHA control. Fold changes in hTERT 
gene expression compared to TatHA control in breast can-
cer cell lines. HCC1937 and HCC1599 cells were treated for 
24 hours with 2 μM Tat fusion proteins. RNA was isolated 
and RT-qPCR performed as described under Materials and 
Methods. The asterisks (*) indicate statistically significant fold 
changes in gene expression. A significant 3.5-fold repression 
of hTERT gene expression was observed in HCC1937 cells 
treated with E2F-1/TatHA proteins in comparison to treat-
ment with TatHA control proteins (p < 0.0024). Repression 
of hTERT in HCC1937 cells treated with E132/TatHA pro-
teins versus the TatHA control proteins was not statistically 
significant (p < 0.6484). A 3.3-fold repression of hTERT was 
observed in HCC1599 cells treated with E2F-1/TatHA pro-
teins versus the TatHA control protein (p < 0.0001). hTERT 
gene expression was slightly increased (1.15-fold increase) in 
HCC1599 cells treated with E132/TatHA proteins versus the 
TatHA control proteins (p < 0.0102). The results are means 
+/- SEM of three separate experiments (HCC1937, n = 17; 
HCC1599, n = 18).
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does not result in permanent genetic manipulation. In
addition, therapeutic treatment with these TFPs is com-
pletely reversible, permitting transient repression of target
genes.
Conclusion
Our lab refined an efficient protocol to produce and
purify E2F-1/TatHA and E132/TatHA proteins by using
strong denaturants, FPLC and dialysis. The biologically
active E2F-1/TatHA, E132/TatHA and TatHA proteins
effectively transduced greater than 95% of cell lines tested
as detected via immunocytochemistry. Following treat-
ment of cell lines with E2F-1/TatHA, E132/TatHA and
TatHA proteins for 24 hours, our data revealed significant
repression of hTERT with E2F-1/TatHA treatment.
In HCC1937 cells, hTERT was repressed 3.5-fold by E2F-
1/TatHA in comparison to E132/TatHA and the TatHA
peptide controls. In HCC1599 cells, hTERT was also
repressed with E2F-1/TatHA treatment by 4.0-fold when
compared to the E132/TatHA control. A slightly lower
hTERT repression of 3.3-fold was observed with E2F-1/
TatHA in the HCC1599 cells when compared to the
TatHA control. No differences were observed in cell lines
with wildtype versus mutant BRCA1 genes. Overall, these
results suggest that transduction of E2F-1/TatHA fusion
proteins in vitro is a moderately effective repressor of
hTERT expression in the primary ductal breast cancer cell
lines HCC1937 and HCC1599. The hypothesized repres-
sion of telomerase activity in infiltrating ductal carcinoma
cells via E2F-1 repressor proteins is supported by signifi-
cant hTERT repression in both HCC1937 and HCC1599
cells.
The breast cancer cell lines utilized in our study represent
non-metastatic primary ductal carcinoma cell lines.
HCC1937 cells were derived from a TNM stage IIB, grade
3 breast tumor, and the HCC1599 cell line was started
from a TNM stage IIIA, grade 3 primary ductal carcinoma
[20]. Our research suggests that E2F-1/TatHA is an effec-
tive repressor of hTERT in primary ductal carcinoma cells
that are actively expressing telomerase. Although we have
not fully investigated metastatic breast carcinoma cell
lines, preliminary studies (results not shown) with MDA-
MB-231 and MDA-MB-435S cells, both of which are
derived from pleural effusions from metastatic breast can-
cer (TNM stage IV) [17], did not reveal statistically signif-
icant repression of hTERT. Therefore, the E2F-1/TatHA
proteins investigated in this study would be potential
adjuvants to therapy in nonmetastatic, primary breast
tumors.
Collectively, these studies were undertaken to develop an
effective technique to achieve complete transduction of
cancer cells with fusion peptides. The hypothesized
repression of telomerase activity in infiltrating ductal car-
cinoma cells via E2F-1 repressor proteins is supported by
significant hTERT repression in both HCC1937 and
HCC1599 cells. Future experiments will further investi-
gate the transcriptional repressive effects of E2F-1 and its
effects on cell-cycle progression and telomerase repres-
sion. To conclude, this therapy can initiate a sufficient
biological effect to induce cell death in cancer cells but is
expected to be safe enough to permit normal cells to
recover from treatment without genetic alteration. Further
research with E2F-1 TFPs will continue to explore their
therapeutic potentials and benefits in the field of breast
cancer research.
Methods
Vector DNA
The vectors pCMV E2F-1 and pCMV E132 were obtained
from Dr. Karen Vousden (Beatson Cancer Institute, UK)
and the pTatHA vector was a kind gift from Dr. Steven
Dowdy (University of Washington, St. Louis, MO).
E2F-1/TatHA and E132/TatHA constructs
The wildtype E2F-1 gene was directly cloned into the
pTatHA vector via NcoI and EcoRI restriction enzyme
sites. The E132 vector (mutant E2F-1) contained an artifi-
cial EcoRI site in the DNA binding domain and could not
be directly inserted into pTatHA's multiple cloning site
(MCS). Therefore, the E132 gene was modified using 5'
site-directed mutagenesis via PCR from plasmid pCMV-
E132 using sense primer: 5'-gcgcgcaaccATGGCCTT-
GGCCGGG-3'and antisense primer: 5'-gcgcagcatgcG-
GATCCAGCCCTGTC-3' to generate artificial NcoI and
SphI sites (underlined in primer sequences). The PCR
reaction used 2 Units Vent Taq polymerase (New England
Biolabs, Beverly, MA), 1× Thermapol buffer (New Eng-
land Biolabs, Beverly, MA), 500 nM of sense and antisense
primers and 5% DMSO. The PCR product was amplified
under the following conditions: initial cycle 94°C- 3 min-
utes, 55°C- 1 minute, 72°C- 1 minute followed by 23
cycles of 94°C- 1 minute, annealing, 55°C- 1 minute,
72°C- 1 minute and a final extension of 72°C for 7 min-
utes. The pTatHA DNA was digested with restriction
enzymes NcoI and SphI and purified using phenol/chlo-
roform extraction. The E132 PCR product was digested
with NcoI-SphI and subcloned into the NcoI-SphI sites of
pTatHA to yield E132/TatHA using a Klenow-Kinase-
Ligase (KKL) protocol [24].
Recombinant protein production
E2F-1/TatHA and E132/TatHA plasmids were trans-
formed into BLR(DE3)pLysS competent cells (Novagen,
Madison, WI) and recombinant proteins produced via
inoculating 2 ml 2YT broth with single transformed colo-
nies. After incubation in shaking water bath (225 rpm) for
12–14 hours, 3 ml of fresh 2YT broth, 0.5 μg/ml ampicil-Molecular Cancer 2008, 7:28 http://www.molecular-cancer.com/content/7/1/28
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lin, and 0.4 mM isopropyl-beta-D-thiogalactopyranoside
(IPTG) were added to cultures. Cultures were incubated
an additional 6 hours to produce recombinant proteins
via IPTG stimulation. Cultures were centrifuged at 6000 ×
g for 10 minutes and cell pellets resuspended in 100 μl of
20 mM Tris buffer (pH 8.0) followed by quantitation
using a BCA™ Protein Assay Kit (Pierce Biotechnologies,
Inc., Rockford, IL) with BSA standards. 2× Laemmli Sam-
ple Buffer was added to 50 μg of total cellular protein and
samples were boiled for 3–5 minutes and immediately
placed on ice [25]. Samples were then loaded onto 12%
SDS-PAGE gels and run on a Mini-PROTEAN® 3 (Bio-Rad
Laboratories, Hercules, CA) protein electrophoresis unit
using the Laemmli buffer system. Prestained 1 kb protein
ladders (Fermentas Life Technologies, Hanover, MD)
were also run on each gel to determine protein size (refer
to Figure 1).
Western blotting
For Western blotting experiments, duplicate gels were run
simultaneously- one gel for western blotting and a second
gel for Coomassie blue staining. The gel designated for
western blotting was transferred to nylon membranes
using a Trans-Blot SD Semi-Dry Electrophoretic Transfer
Cell (Bio-Rad Laboratories, Hercules, CA) according to
manufacturer's instructions using 1× TBS-T transfer buffer.
Recombinant protein production was verified using pri-
mary mouse monoclonal anti-HA antibodies (1:1,000
dilution) (CRP, Inc., Denver, PA) and secondary HRP-
labeled goat anti-mouse antibodies (1:25,000 dilution)
(KPL, Inc., Gaithersburg, MD). Membranes were blocked
with TBS-T/5% milk solution for 1 hour, incubated with
primary anti-HA antibody for 1 hour, washed 3 times for
10 minutes each, and incubated with secondary HRP anti-
body for 1 hour. Following additional washings (3 × 10
minutes), western blots were developed with SuperSignal
West Pico Chemiluminescent Substrate (Pierce Biotech-
nology, Inc., Rockford, IL) according to manufacturer's
instructions. Blots were exposed to X-ray film and devel-
oped.
Large-scale recombinant protein production
Recombinant E2F-1/TatHA and E132/TatHA proteins
were purified under denaturing conditions with affinity
chromatography using a modified procedure from Amer-
sham Pharmacia [26]. Single colonies from protein
expressing cultures inoculated 200 ml of 2YT broth sup-
plemented with ampicillin (50 μg/ml) and were incu-
bated at 37°C while shaking at 225 rpm for 16–18 hours.
An additional 300 ml of broth was added along with fresh
ampicillin and IPTG (400 μM), and cultures incubated an
additional 6 hours. Cultures were centrifuged for 10 min-
utes at 6000 × g, and the pellets frozen at -20°C. Cell pel-
lets were thawed for 20 minutes at 37°C, and 25 ml of
Buffer 1 (20 mM Tris™-HCl, pH 8.0) added to resuspend
the cells with vigorous pipetting. Cells were sonicated on
ice (3 × 15 sec) and centrifuged (10 min × 6000 g). Cell
pellets containing the inclusion bodies were then resus-
pended in 25 ml Buffer 2 (2 M urea, 20 mM Tris-HCl, 0.5
M NaCl, 2% Triton™ X-100, pH 8.0). Samples were again
sonicated on ice and centrifuged as described above. Pel-
lets were resuspended in 25 ml Buffer 2 to wash the inclu-
sion bodies and recentrifuged. A final wash of 25 ml of
Buffer 1 was then performed, and following centrifuga-
tion, pellets were either used immediately or frozen at -
20°C for a maximum of two weeks prior to use.
Preparation of inclusion bodies for FPLC
Cell pellets were resuspended in 5–10 ml Buffer A1 (6 M
guanidine-HCl, 0.5 M NaCl, 20 mM Tris-HCl, 20 mM imi-
dazole, 5 mM β-mercaptoethanol, pH 8.0) by stirring at
room temperature for 60 minutes to solubilize recom-
binant proteins. Samples were centrifuged at 20,000 × g
for 15 minutes to pellet residual cell debris. Protein super-
natant containing denatured, soluble proteins was
removed from residual cell debris. Supernatant was fur-
ther clarified by passage through a 0.45 μM filter (Milli-
pore, Bellerica, IL) to further remove any particles.
Isolation of recombinant proteins using affinity 
chromatography
HisTrap™ Ni++ charged columns (Amersham Pharmacia,
Piscataway, NJ) were equilibrated with 5 ml Buffer A1 and
the proteins loaded at a flow rate of 0.5 ml/minute. Col-
umns were washed with an additional 10 ml of Buffer A1
followed by a wash of 10 ml of Buffer A2 (6 M urea, 0.5 M
NaCl, 20 mM Tris-HCl, 20 mM imidazole, 5 mM β-mer-
captoethanol, pH 8.0). A linear gradient from 6 M to 0 M
urea was then performed to remove the denaturant and
start refolding the proteins on the HisTrap™ column by
gradually replacing Buffer A2 with Buffer B1 (0.5 M NaCl,
20 mM Tris-HCl, 20 mM imidazole, 5 mM β-mercap-
toethanol, pH 8.0). A total volume of 40 ml of Buffer B1
was used to perform the gradient wash. The purified,
refolded proteins were then eluted with Buffer B2 (0.5 M
NaCl, 20 mM Tris-HCl, 500 mM imidazole, 5 mM β-mer-
captoethanol, pH 8.0) using a gradient of 0 mM to 500
mM imidazole in the buffer. Fractions containing the
purified protein were analyzed by SDS-PAGE gel electro-
phoresis and quantified with the BCA™ Protein Assay Kit
(Pierce Biotechnology, Inc., Rockford, IL).
Dialysis of recombinant proteins into cell culture media
E2F-1/TatHA and E132/TatHA recombinant proteins were
diluted with Buffer B2 to a concentration of 0.5 mg/ml to
avoid protein precipitation cascades and injected into 12
ml Slide-A-Lyzer® Dialysis Cassettes (Pierce Biotechnol-
ogy, Inc., Rockford, IL) using 21-gauge, 1-inch beveled
hypodermic needles. Proteins were dialyzed in 1× PBS for
2 hours at room temperature. The cassettes were placed inMolecular Cancer 2008, 7:28 http://www.molecular-cancer.com/content/7/1/28
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fresh 1× PBS for an additional 2 hours at room tempera-
ture and then dialyzed overnight in appropriate cell cul-
ture media for designed cell line experiments. Following
dialysis, proteins were removed from cassettes and placed
in sterile 50 ml conical centrifuge tubes and centrifuged at
9400 × g for 15 minutes to remove any protein precipitate.
Protein supernatant was removed and the final concentra-
tions of recombinant proteins determined using the
Coomassie Plus™ Bradford Assay (Pierce Biotechnology,
Inc., Rockford, IL) and SDS-PAGE gels using BSA protein
standards. Contamination of proteins was minimized by
passage through 0.2 μM filters (Millipore, Bellerica, IL).
Purified protein was supplemented with 10% heat-inacti-
vated FBS (Hyclone, Logan, UT) and 50 IU/ml penicillin/
0.05 mg/ml streptomycin. Prior to testing on carcinoma
cell lines, various μM concentrations were tested to deter-
mine optimal transduction at different time points using
immunocytochemistry to monitor cellular uptake of E2F-
1/TatHA and E132/TatHA.
Synthesis of TatHA control protein
The TatHA control protein was artificially synthesized
(amino acid sequence: YPYDVPDYAYGRKKRRQRRR)
[27] on a Ranin Symphony/Multiplex Peptide Synthesizer
(Center for Integrated BioSystems, Logan, UT). The TatHA
peptide was reconstituted using Cellgro™ RNase free/
DNase/Protease free dH20 for cell culture (Mediatech Inc.,
Herndon, VA) and stored at -70°C at a working concen-
tration of 1 mg/ml [28].
Primary carcinoma cell culture
Primary infiltrating ductal breast carcinoma cell lines
HCC1937 (ATCC number: CRL-2336) and HCC1599
(ATCC number: CRL-2331) were obtained from the
American Type Culture Collection (Manassas, VA). The
cells were grown in RPMI-1640 medium supplemented
with 10% FBS, 50 IU/ml penicillin/0.05 mg/ml strepto-
mycin, 10 mM HEPES, and 1 mM sodium pyruvate. Cells
were grown in a 37°C humidified incubator with 5%
CO2. Cell lines were grown in 25 cc2 and 75 cc2 tissue cul-
ture flasks and passaged every 2–4 days when 70–80%
confluent. Cells were detached from flasks using 0.25%
trypsin, 0.03% EDTA solution according to standard cell
culture protocols [29].
Immunocytochemisty
HCC1937 and HCC1599 cells were exposed to 2 μM E2F-
1/TatHA, E132/TATHA, and TatHA fusion peptides for
various time points: 1, 6, 12 and 24 hours. Cells were
washed 3 times with 1× PBS, fixed for 30 minutes in 3.7%
formaldehyde and permeabilized with 0.5% Triton X-100
in 1× PBS for 30 minutes. Cells were blocked for 30 min-
utes with 1% FBS and 0.1% Tween-20 in 1× PBS. Cells
were incubated for 60 minutes with primary mouse HA
antibodies (1:1000 dilution in 1× PBS), washed 3 times
for 10 minutes each, and incubated for 60 minutes with a
secondary FITC-labeled goat anti-mouse antibody (1:250
dilution in 1× PBS) (KPL, Inc., Gaithersburg, MD). Cells
were then washed, and incubated for 15 minutes with 1
μM TO-PRO-3 iodide (Molecular Probes, Eugene, OR) to
counterstain the cell nuclei. Cells were then mounted on
slides using Prolong® Antifade (Molecular Probes, Eugene,
OR) and images captured with Bio-Rad MRC 1024 Laser
Scanning Confocal Microscope (see Figure 2).
Cell culture experiments with recombinant proteins
HCC1937 and HCC1599 cells were seeded at a density of
2 × 105 cells/well in CellStar® 6-well tissue culture plates.
HCC1937 (adherent) cells were allowed 24 hours to
adhere to plates before recombinant proteins were added.
HCC1599 (suspension) cells were seeded directly into
wells with TFPs. After 24 hours of co-incubation, RNA was
isolated and analyzed via RT-qPCR as described below.
RNA isolation, reverse transcription and quantitative PCR
Total RNA was isolated from cells using the Mini RNA Iso-
lation II™ kit (Zymo Research, Orange, CA) using the fol-
lowing protocol. After treatment with TFPs, adherent cell
lines were washed at least three times with 1× PBS and
detached from tissue culture plates using 0.5 ml
HyQ®tase™ (Hyclone, Logan, UT). Cells were added to 1.8
ml microcentrifuge tubes and pelleted by centrifugation at
14,000 rpm for 1 minute. Supernatant was decanted and
excess fluid removed via micropipetting. A 600 μl volume
of ZR RNA Buffer was added to cells, tubes vortexed 30
seconds, and sample transferred to a Zymo-Spin III col-
umn placed in a 2 ml collection tube. Zymo-Spin III col-
umn was centrifuged at 14,000 rpm for 1 minute. A 350
μl volume of RNA Wash Buffer was added to the Zymo-
Spin III column and centrifuged as described above to
wash column. A second wash was performed with 350 μl
RNA Wash Buffer to further clean RNA. The spin column
was then transferred to a sterile 1.8-ml microcentrifuge
tube. A 50 μl volume of RNase-free water was added
directly to the membrane of the Zymo-Spin III Column
and column centrifuged for 15 seconds to elute RNA. The
eluted RNA was quantified using a Nanodrop® ND-1000
Spectrophotometer (Nanodrop Technologies, Wilming-
ton, DE).
A two-step reverse transcriptase-quantitative polymerase
chain reaction (RT-qPCR) was performed for all the exper-
iments described in this study. A 200 ng quantity of RNA
was treated with DNase (1 U/μg) (Fisher Scientific, Pitts-
burgh, PA) in a 10 μl digestion reaction volume including
a final 1× concentration of RQ1 RNase-Free DNase Reac-
tion Buffer (40 mM Tris-HCl, 10 mM MgSO4, 1 mM
CaCl2, pH 8.0) (Fisher Scientific, Pittsburgh, PA). Samples
were incubated at 37°C for 30 minutes followed by the
addition of 1 μl of RQ1 DNase Stop Solution (20 mMMolecular Cancer 2008, 7:28 http://www.molecular-cancer.com/content/7/1/28
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EGTA, pH 8.0) (Fisher Scientific, Pittsburgh, PA) and sam-
ples incubated at 65°C for 10 minutes to inactivate the
DNase. The 11 μl volume of DNase-digested RNA was
used for the RT-PCR reaction.
Production of cDNA from total RNA
The 11 μl volume containing the RNA was combined with
2  μl random hexadeoxynucleotides (0.5 μg/ul) (Fisher
Scientific, Pittsburgh, PA) and a 4 μl volume of dNTP mix
(10 mM per dNTP) (New England Biolabs, Beverly, MA).
Tubes were heated for 5 minutes at 70°C to anneal prim-
ers to RNA, samples then placed on ice, and the following
components added to the reaction tube to yield a 20 μl
volume: 2 μl 10× RT Buffer (50 mM Tris-HCl, 75 mM KCl,
3 mM MgCl2, 10 mM DTT, pH 8.3) (New England
Biolabs, Beverly, MA), 10 U of RNase Inhibitor (Fisher Sci-
entific, Pittsburgh, PA), and 25 U M-MuLV Reverse Tran-
scriptase (New England Biolabs, Beverly, MA). Reaction
tubes were incubated at 42°C for 1 hour to generate
cDNA, and the RT enzyme heat inactivated at 95°C for 5
minutes. A 0.5 μl volume containing 2.5 U of RNase H
(New England Biolabs, Beverly, MA) was added to tubes
and samples incubated at 37°C for 20 minutes to degrade
RNA. RNase H was then heat inactivated at 95°C for 5
minutes. Each cDNA pool was diluted to 50 μl and stored
at -20°C until analyzed via real-time qPCR reaction.
Real-time quantitative PCR
Real-time qPCR was performed using the MyiQ™ Single
Color Real-Time PCR Detection System (Bio-Rad, Her-
cules, CA). A 2 μl sample of each cDNA pool served as
template for the qPCR reaction using IQ™ SYBR® Green
Supermix (Bio-Rad, Hercules, CA) and 300 nM of each
primer: hTERT sense & antisense primers (5'-GGAG-
CAAGTTGCAAAGCATTG-3' & 5'-CCCACGACGTAGTC-
CATGTT-3') [30], B-actin sense & antisense primers (5'-
CACTCTTCCAGCCTTCCTTCC-3'& 5'-CTGTGTTGGCGT-
ACAGGTCT-3') [31]. All qPCR reactions were performed
in at least triplicate for each sample using 96-well plates.
The following cycling program was used for all primer
sets. Initial denaturation step at 95°C for 3 minutes fol-
lowed by 45 cycles at 94°C- 30 sec., 59.5°C- 30 sec.,
72°C- 30 sec., and an 80°C- 15 sec. data acquisition step.
A melt curve was performed for every reaction plate. Fold
changes in gene expression were determined using the 2-
ΔΔCTmethod [32]. The CT data were imported into Micro-
soft Excel. CT values for hTERT and B-actin were averaged
for each sample, and ΔCT calculated (ΔCT = CT, avg. hTERT –
CT, avg. B-actin). ΔΔCT was calculated in the following man-
ner: ΔΔCT = Avg. ΔCT, hTERT from E2F-1 or E132 TFP treatment – ΔCT,
hTERT from TatHA control. Mean fold change in gene expression
was determined by the following calculation: 2^-ΔΔCT.
Statistical analysis
Statistical significance of mean fold changes in gene
expression was determined by Student's paired t-test using
Microsoft Excel and Analyze-it™ (Analyze-it Software,
Ltd., vsn 1.71). Results were considered significant if two-
tailed P values were < 0.05.
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